# Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products

> **NCT05010174** · — · TERMINATED · sponsor: **Medeor Therapeutics, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Immune Tolerance

## Interventions

- **DRUG:** MDR product

## Key facts

- **NCT ID:** NCT05010174
- **Lead sponsor:** Medeor Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-11
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05010174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05010174, "Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05010174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*